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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not “does
honey provide therapeutic relief to patients with chemotherapy induced oral mucositis?”
STUDY DESIGN: Review of one double-blind randomized control trial (RCT), one RCT, and
one cohort study.
DATA SOURCES: All articles were published in English and taken from peer-reviewed
journals using PubMed. All articles were published between 2012-2019.
OUTCOMES MEASURED: The outcomes measured included decreased severity of oral
mucositis measured in one study using the WHO Oral Toxicity Scale and another using WHOSTC (Stomatitis Toxicity Criteria). Another outcome measured was recovery time, which was
defined as the number of days from the start of treatment to when complete healing of every
ulcer occurred.
RESULTS: The double-blind RCT performed by Raeessi et al. showed a statistically significant
difference (p-value<0.001) after treatment with honey when compared to the steroid group. The
mean severity of oral mucositis (OM) was 1.43± 0.75 after treatment with the steroid compared
to 0.90 ± 0.65 after treatment with honey. The mean difference between the honey and control
group was 0.51. Abdulrhman et al. conducted a RCT that showed a statistically significant
difference (p-value <0.005) between the mean recovery time (days) of children with OM in the
benzocaine group vs. the honey group. For the benzocaine group, the recovery time mean was
6.10±2.47. The honey group recovery time mean was 4.25±1.25. The mean difference between
the two groups was 1.85. The cohort study performed by Singh et al. showed a statistically
significant reduction (p-value<0.01) in the severity of OM by day 7 between the control group
and the experimental honey group. By day 7, 27 (54%) children had Grade 0 OM in the control
group, while 46 (92%) children had Grade 0 OM in the honey group. The calculated NNT was 3,
the ABI was 0.38, and the RBI was 0.70.
CONCLUSION: All three studies demonstrated that honey provides a statistically significant
decrease in severity of OM and recovery time, demonstrating the therapeutic relief honey
provides to patients with chemotherapy induced OM.
KEY WORDS: honey, oral mucositis
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INTRODUCTION
Oral mucositis (OM) is one of the most common and recurrent side effects of
chemotherapy treatment. OM results from breakdown of the oral mucosal lining, leading to ulcer
formation. Before ulcer formation occurs, endothelial cells become damaged and inflammatory
cytokines and reactive oxygen species are activated at the mucosal level.1,2 Between 40-80% of
chemotherapy patients suffer from OM, which can adversely affect speech and nutrition and
result in malnutrition and dehydration.1,2 Patients who develop OM can also develop infections
that require prolonged hospital stays. This increases treatment costs and may require clinicians to
modify chemotherapy treatment protocols and doses for their patients.
Unfortunately, this common side effect of chemotherapy is often overlooked by clinical
treatment teams who are capable of preventing and treating this condition.1,2 Studies show that
the estimated incremental cost of OM per cycle of chemotherapy is $3,700.3 While it is unknown
how many healthcare visits are associated with this condition each year, one study showed that in
a population of cancer patients receiving chemotherapy, the average rate of hospitalization was
one admission per year with 40% of admissions identified as being related to a chemotherapy
issue.4
Often appearing 7-14 days after initiation of chemotherapy, OM results in erythema,
edema, an ulceration that creates a burning sensation, or the development of painful ulcers that
can impact oral function. OM usually resolves in 2-3 weeks after a chemotherapy infusion.1,2
OM has a complex pathobiology on how oral mucosa damage occurs as a result of
chemotherapy. Risk factors for the development of OM include younger age, poor oral hygiene,
and the nutritional status of a patient.2 Chemotherapy drugs that commonly cause OM include
methotrexate, etoposide, cytarabine, fluorouracil, and doxorubicin.2 Some of the usual methods
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used to treat OM include oral hygiene protocols (frequent brushing/flossing), antimicrobial
agents (chlorhexidine), local anesthetics (benzocaine), and steroids (betamethasone).1,2,5,6 More
recently oral cryotherapy, where ice chips are used to cool mucous membranes during infusions,
is a readily available treatment intervention.7
While methods exist to address this condition, few efficacious interventions are available
for management of chemotherapy induced OM. There is currently no specific, single standard
method to prevent and treat OM.1 As a result, research has been investigating the impact of
honey on OM. Honey, which is produced by honeybees (Apis mellifera), has H2O2, which is
produced by glucose oxidase and attributes to honey’s antimicrobial property.5 Honey can reduce
inflammation and accelerate tissue regeneration, which explains its therapeutic use in treating
conditions such as gingivitis and periodontal disorders.5 This paper analyzes one double-blind
RCT, one RCT, and one cohort study to evaluate the therapeutic relief honey provides for
chemotherapy induced OM.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not “does honey
provide therapeutic relief to patients with chemotherapy induced oral mucositis?”
METHODS
The population targeted for this review included patients with chemotherapy induced oral
mucositis (OM). The intervention being investigated for therapeutic relief of oral mucositis is
honey in comparison to benzocaine gel, betamethasone steroid, and analgesic/antiseptic gel
(choline salicylate 8.7% w/w + benzalkonium 0.01% w/w + lignocaine HCL 2.0% w/w). The
outcomes being measured are decreased severity of oral mucositis and recovery time. All articles
were published in English in peer-reviewed journals between 2012-2019 and obtained from
PubMed. The articles were selected based on relevance and if they included patient oriented
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outcomes. Keywords used to obtain the articles included “honey” and “oral mucositis”. Inclusion
criteria were articles published in the last 10 years in English that involved humans. Exclusion
criteria included systematic reviews and research published before 2012. A summary of statistics
reported includes p-values, NNT, RBI, and ABI. The studies included in this EBM review
include a double blind RCT, a RCT, and a cohort study. Table 1 includes demographics and
characteristics of the included studies.
Table 1. Demographics & Characteristics of Included Studies
Study

Type

# Pts

Raeessi
(2014)5

Double
Blind
RCT

75

Age
(yrs)
1580

Inclusion

Exclusion

W/D

Interventions

Patients 15-80
years old with
oral mucositis
after
chemotherapy

Patients with
other systemic
disease and/or
abnormal
laboratory tests

13

Oral Honey
Regimen
(600 g
solution
contained
300 g of
honey), 3 tsp
every 3
hours for 1
week

Patients with
coexisting
Diabetes Mellitus,
presence of
neutropenia,
presence of
severe
periodontitis,
previous
treatment for oral
mucositis,
administration of
antiviral or
antifungal therapy
Adults, Children
with Diabetes
Mellitus

0

Topical
Honey,
received 0.5
g honey/kg
(maximum
15 g) applied
to affected
oral mucosa
3 times daily
until healing
or for 10
days

0

Topical
Honey 1-2
ml 4 times
daily until
cure of oral
mucositis

Abdulrhman RCT
(2012)6

90

2-18

Children 2-18
years old with
acute
lymphoblastic
leukemia and
chemotherapyrelated oral
mucositis
grade 2 and 3

Singh
(2019)1

100

<18

Children <18
who
developed
Grade I and II
oral mucositis
after
chemotherapy

Cohort
Study
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OUTCOMES MEASURED
The outcomes measured in this EBM review included decreased severity of oral
mucositis measured using the WHO Oral Toxicity Scale and the WHO-STC (Stomatitis Toxicity
Criteria), as well as recovery time that was defined as the number of days from the start of
treatment to when complete healing of all ulcers occurred.6 The WHO scales grade OM in the
following manner: Grade 0 (none) None, Grade 1 (mild) oral soreness, erythema, Grade 2
(moderate) erythema, ulcers, solid diet tolerated, Grade 3 (severe) oral ulcers, liquid diet only,
Grade 4 (life-threatening) oral feeding is impossible, requires parental nutrition.1,5
RESULTS
Raeessi et al. conducted a double-blind RCT that compared the effects of oral honey and
betamethasone in adults with chemotherapy induced OM. A total of 75 participants (15-80 years
old) with chemotherapy induced OM during a period of three years at Baqiyatallah University
Hospital in Tehran, Iran were selected for this study between 2012-2013.5 Individuals were
chosen based on specific inclusion and exclusion criteria noted in Table 1. Participants were
randomized using an online statistical computing web programming into two groups-one group
receiving the steroid betamethasone and another group receiving oral honey.5 In order to keep
consistency between all three studies, this review will not discuss the third comparison
intervention measured in this study. The treatments for each group were encoded confidentially
and distributed randomly to participants. Participants were instructed to sip and swallow 3
teaspoons of their prescribed treatment and were asked to repeat this process every three hours
for one week.5 There were 13 participants who were lost to follow up or discontinued the
intervention, leaving 62 participants left to be analyzed at completion of the study. The losses
were equal across each studied group.5
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Severity of OM was clinically evaluated before treatment and one week after the
intervention began. Five physicians categorized participants on the basis of the WHO Oral
Toxicity Scale for grading OM. Grading was assigned on a scale of 0-3 (0=no OM, 1=mild,
2=moderate, 3=severe), and was used as the main outcome measurement to compare the
effectiveness of the interventions.5 Table 2 depicts the changes in the mean of OM severity and
standard deviation (± STD) before and after treatment for each intervention. A statistically
significant difference after treatment was measured as a p-value <0.001 between interventions.5
For the steroid group, the mean severity of OM was 2.52 ± 0.51 before treatment and 1.43± 0.75
after treatment, with a mean difference of 1.09.5 For the honey group, the mean severity of OM
was 2.50 ±0.51 before treatment and 0.90 ± 0.65 after treatment, with a mean difference of 1.60.5
The mean difference between the honey and control group was 0.51.5 This study did not discuss
adverse events, safety concerns, or tolerability among its participants.
Table 2. WHO Oral Toxicity Scale Mean± STD Change in Severity of OM Before and
After Treatment and Statistical Significance5
Before Treatment
After Treatment
Mean Change
P-value
from Baseline
(Mean±STD)
(Mean± STD)
(Calculated)
Steroid
1.09
0.001
2.52± 0.51
1.43± 0.75
Group
Honey
1.60
2.50± 0.51
0.90± 0.65
Group
Both
0.51
groups
Abdulrhman et al. conducted a RCT that compared the effects of topical honey and
benzocaine gel in children with chemotherapy induced OM. A total of 90 children (2-18 years
old) with acute lymphoblastic leukemia (ALL) and chemotherapy induced OM (grade 2 and 3)
were selected for this study. Children were recruited from the Hematology-Oncology Unit of
Children’s Hospital of Ain Shams University in Egypt from 2010-2011.6 Children were chosen
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based on the inclusion and exclusion criteria noted in Table 1. Children were admitted to the
hospital during the study period to avoid follow-up loss and ensure compliance. Children were
randomized into two groups-one group received benzocaine 7.5% gel three times daily and
another group received 0.5g honey/kg applied topically to the oral mucosa three times daily until
healing occurred or for 10 days, which is usually the maximum healing time frame for OM.6 In
order to keep consistency between all three studies, this review will not discuss the third
comparison intervention measured in this study. All children received routine oral care (tooth
brushing followed by a saline rinse three times daily) and were followed up daily.6 Application
of both treatments was applied by a resident or nursing staff member under researcher
supervision.6 The outcome measured was recovery time, which was defined as the number of
days from the start of treatment to when complete healing of OM occurred.6 No children were
lost to follow up for this study and all topical treatments were tolerated with no gastrointestinal
adverse effects or hypersensitivity reaction.6
Table 3 depicts the mean recovery time (days) and standard deviation (± STD) for both
interventions for children with grade 2 and 3 OM. A statistically significant difference was
measured as a p-value <0.005 between interventions.6 For the benzocaine group, the recovery
time mean was 6.10±2.47. The honey group had a recovery time mean of 4.25±1.25. The mean
difference between the two groups was 1.85.6
Table 3. Recovery Time Mean± STD in Children with Chemotherapy Induced OM and
Statistical Significance6
Recovery time (days) Mean difference
P-value
(calculated)
Mean ± STD
Benzocaine
0.005
6.10±2.47
Group
Honey Group 4.25±1.25
Both Groups
1.85
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Singh et al. was a cohort study that compared topical honey to a routine practice of
analgesic and antiseptic gel in children with chemotherapy induced OM. A total of 100 children
from the Hematology-Oncology Unit at APC, PGIMER, Chandigarh were selected for this study
in India.1 Children were selected based on specific inclusion and exclusion noted in Table 1.
Two groups (experimental and control) with 50 children in each were identified, with the
outcome of the study assessed by a blinded observer who assessed the severity of OM using the
WHO-STC scale every other day until cure in both groups.1 The experimental group received
topical honey while the control group received a routine practice of analgesic and antiseptic gel.
Caregivers of the children were trained through demonstration on how to apply topical honey on
OM.1 Caregivers applied 1-2mL of honey four times daily from the start of the study until cure
of OM.1 The control group only received the analgesic and antiseptic gel. No children were lost
to follow up.
This EBM review will focus on the results of day 7. On the 7th day there was a
statistically significant reduction in the severity of OM with a measured p-value<0.01.1 As
shown in Table 4, by day 7, 27 (54%) children had Grade 0 OM in the control group, while 46
(92%) children had Grade 0 OM in the experimental honey group. The calculated NNT was 3,
which showed a large treatment effect that implies clinical significance. The ABI was 0.38 and
the RBI was 0.70 as shown in Table 5. No adverse effects, tolerability, or safety concerns were
mentioned in this study.
Table 4. Number of Children with Grade 0 OM on Day 7 in Both Groups and Statistical
Significance1
Control group n (%) Experimental group n (%) P-value
27(54)

46(92)

0.01

Table 5. Calculations for Treatment from Singh et al.1
Study
CER
EER
RBI
Singh et al.
0.54
0.92
0.70

ABI
0.38

NNT
3
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DISCUSSION
OM can be a debilitating condition for those who are battling cancer. The goal of this
systematic review was to determine if honey provided therapeutic relief to patients with
chemotherapy induced OM. All three articles reviewed demonstrated a significant improvement
of OM with the use of honey. For Raeessi et al. there was a significant difference (p<0.001) in
the mean severity of OM between the steroid group (2.52 ± 0.51 before treatment and 1.43±
0.75 after treatment) and the honey group (2.50 ±0.51 before treatment and 0.90 ± 0.65 after
treatment), meaning that honey reduced the severity of OM in adults more than the use of the
steroid.5 The mean change from baseline difference between both groups was 0.51,
demonstrating a large treatment effect in favor of honey.
Singh et al. and Abdulrhman et al. both demonstrated the positive impact of honey on
OM in children. Abdulrhman et al. demonstrated that there was a statistically significant
difference (p<0.005) between interventions in their mean recovery time. The mean recovery time
for the benzocaine group was 6.10 days, while the honey group had a recovery time mean of 4.25
days. The mean difference was 1.85 days, which shows that honey produced faster healing of
Grade 2 and 3 OM than the use of benzocaine.6 Singh et al. focused on children with Grade 1
and 2 OM. By day 7, 54% of children in the control group had Grade 0 OM compared to 92%
from the experimental honey group, demonstrating a statistical significant difference (p<0.01)
between both groups in terms of decreased severity of OM with honey providing the most
improvement.1 The treatment effect of honey was large, with NNT=3.
One limitation for Singh et al. was there was no intention-to-treat analysis and the
children were not blinded to their treatment or randomized. The study also excluded children
with DM.1 There was also a disparity between the control and experimental group on the 1st day
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of enrollment. In the experimental group, 96% of children had grade II OM compared to 78% in
the control group, demonstrating that from the first day of enrollment there were children with a
more severe grade of OM in the experimental group compared to the control group.1 Limitations
for Abdulrhman et al. and Raeessi et al. also existed due to the exclusion of participants with
certain preexisting conditions as noted in Table 1. Abdulrhman et al. also states that the better
distribution and amount of honey used in the oral cavity could have contributed to its outcome.6
The benefit to this intervention is that honey is widely available to all at any local grocery store
and is cost-effective. The one drawback to this intervention would be that it would not be
recommend to those who have had allergic reactions to honey in the past.
CONCLUSION
All three studies in this EBM review demonstrated that honey provides therapeutic relief
to patients with chemotherapy induced OM. Future studies could include incorporating more
patients who have concurrent systemic diseases to assess if the impact of honey differs for those
who also suffer from additional co-existing medical conditions and enhance generalizability.
Future studies can be designed to include stratified random sampling to ensure both groups being
studied have a more equal, comparable severity grade of OM at baseline to further strengthen the
significance of the results. A more recent study has demonstrated that not only can use of a
honey mouthwash decrease OM severity, but it can also reduce the possibility of weight loss and
encourage weight gain amongst cancer patients.8
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